Weight and metabolic health
Fatty liver and metabolic steatohepatitis
Fat in the liver ranges from simple accumulation to inflammation and scarring. Blood tests alone do not reliably distinguish all stages.
Potential benefits explored
Less liver fat and improved metabolic liver health.
Semaglutide and survodutide have liver-focused human research, while tesamorelin has a narrower HIV-related context. Fat reduction and fibrosis change need separate reporting.
Practical interpretation
Assess fibrosis risk, alcohol, metabolic health and other liver causes. Nutrition, activity and appropriate weight treatment are central.
Meaningful outcomes: Liver-specific clinical endpoints, metabolic markers and weight.
Compare the compounds studied for Fatty liver and metabolic steatohepatitis
Members see the full evidence picture for this condition: every compound studied, graded per condition from strong human evidence through to preclinical-only and negative findings, with human and animal results, risks, combination evidence and cited sources — plus how each compound maps to the research materials we list, with live pricing and stock.
Research reference for laboratory materials only. Not medical advice and not a recommendation for human use. Research cut-off: 30 September 2026.